NuLumin GLP-3

Description

GLP-3 is NuLumin’s designation for retatrutide, a synthetic peptide research compound acting as a triple agonist at the GIP, GLP-1, and glucagon receptors. In laboratory research it is studied across three metabolic pathways at once.

Preclinical literature describes investigations into glucose regulation, energy output, lipid processing, and integrated three-receptor signaling, carried out using cell-based assays and animal studies. Its three-receptor design suits comparative work across metabolic pathways.

Intended use: In vitro and preclinical in vivo laboratory research only. Not approved for human or veterinary use.